CTLA4 and melanoma: In another study, Hanani et al. found that neutralizing IL-2 or blocking its receptor eliminated the antitumor effects and progression associated with the ratio of intra-tumor T effect versus Tregs, commonly induced by CTLA-4 blockade in melanoma mouse models [76].